Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

How Pharma Can Make the Most of Gene Tech CRISPR

Posted on December 18th, 2017 by in Pharma R&D

puzzle-2500333_960_720

The gene-editing technology CRISPR, which stands for ‘clustered regularly interspaced short palindromic repeats,’ is one of today’s most-talked-about scientific innovations. In just a few years, it’s gone from being a barely known entity to becoming a regular presence in scientific literature. Continue reading “How Pharma Can Make the Most of Gene Tech CRISPR” »

As Drug Development Costs Skyrocket, AI Offers Some Hope

Posted on November 20th, 2017 by in Pharma R&D

Last year, researchers from the Tufts Center for the Study of Drug Development published a paper in the Journal of Health Economics that provided an assessment of the current cost for pharmaceutical companies to discover and develop new drugs and biologics. Continue reading “As Drug Development Costs Skyrocket, AI Offers Some Hope” »

Myelo Therapeutics Takes on Unmet Needs in Cancer

Posted on November 17th, 2017 by in Pharma R&D

Many pharmaceutical and biotechnology start-ups have been founded for the purpose of taking on unmet needs. It has often been difficult for the larger, more established pharma companies to focus on these narrower problems, so the leaner, scrappier start-ups are putting their passion and brainpower to the challenges that have yet to be tackled. Continue reading “Myelo Therapeutics Takes on Unmet Needs in Cancer” »

Compliant Monitoring of Adverse Events

Posted on May 24th, 2017 by in Pharmacovigilance

Developing and maintaining a solid strategy for screening for adverse events is critical for every pharmaceutical company. Without one, an adverse event could be reported in scientific literature without the company knowing — and failure to report it to the regulatory authorities could result in a serious warning. Continue reading “Compliant Monitoring of Adverse Events” »

  1. 1
  2. 2
  3. 3